Country
United Kingdom
Lynparza (olaparib) has passed an important threshold in a Phase 3 trial of patients with early breast cancer with the result that it will undergo a primary analysis for efficacy earlier than planned.
Full text available to subscribers only. Click here for information on subscribing to MedNous.